Natarajan Brahma D, Rushing Christel N, Cummings Michael A, Jutzy Jessica Ms, Choudhury Kingshuk R, Moravan Michael J, Fecci Peter E, Adamson Justus, Chmura Steven J, Milano Michael T, Kirkpatrick John P, Salama Joseph K
Department of Radiation Oncology, Duke University, Durham, NC, USA.
Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.
J Radiosurg SBRT. 2019;6(3):179-187.
Follow-up imaging after stereotactic radiosurgery (SRS) is crucial to identify salvageable brain metastases (BM) recurrence. As optimal imaging intervals are poorly understood, we sought to build a predictive model for time to intracranial progression.
Consecutive patients treated with SRS for BM at three institutions from January 1, 2002 to June 30, 2017 were retrospectively reviewed. We developed a model using stepwise regression that identified four prognostic factors and built a predictive nomogram.
We identified 755 patients with primarily non-small cell lung, breast, and melanoma BMs. Factors such as number of BMs, histology, history of prior whole-brain radiation, and time interval from initial cancer diagnosis to metastases were prognostic for intracranial progression. Per our nomogram, risk of intracranial progression by 3 months post-SRS in the high-risk group was 21% compared to 11% in the low-risk group; at 6 months, it was 43% versus 27%.
We present a nomogram estimating time to BM progression following SRS to potentially personalize surveillance imaging.
立体定向放射外科治疗(SRS)后的随访成像对于识别可挽救的脑转移瘤(BM)复发至关重要。由于对最佳成像间隔了解不足,我们试图建立一个预测颅内进展时间的模型。
回顾性分析2002年1月1日至2017年6月30日在三家机构接受SRS治疗BM的连续患者。我们使用逐步回归开发了一个模型,确定了四个预后因素,并构建了一个预测列线图。
我们确定了755例主要为非小细胞肺癌、乳腺癌和黑色素瘤脑转移瘤患者。脑转移瘤数量、组织学类型、既往全脑放疗史以及从初始癌症诊断到转移的时间间隔等因素对颅内进展具有预后意义。根据我们的列线图,高危组SRS后3个月颅内进展风险为21%,而低危组为11%;6个月时,分别为43%和27%。
我们提出了一个列线图,用于估计SRS后脑转移瘤进展时间,以潜在地实现监测成像的个性化。